Integrated DNA Drives Surface Antigen Production in HBeAg-Negative Hepatitis B

The Clinical Challenge of Surface Antigen Persistence

Chronic hepatitis B remains a significant global health burden, with the persistence of the hepatitis B e antigen (HBeAg) serving as a key marker for disease progression and the necessity of antiviral intervention [1, 2]. While the loss of HBeAg represents a degree of immune control, clinicians often face challenges in managing patients who remain positive for the hepatitis B surface antigen (HBsAg) despite low viral replication [1, 3]. Current clinical guidelines emphasize the importance of monitoring viral DNA and surface antigen levels to assess the risk of cirrhosis and hepatocellular carcinoma [3, 4]. However, the underlying intrahepatic mechanisms that drive HBsAg production in different clinical phases of the infection are not fully understood, complicating the pursuit of a functional cure [2, 5]. A recent study examines the distinct patterns of intrahepatic viral DNA to clarify these differences across the natural history of the disease, offering insights into why surface antigen clearance remains so difficult to achieve in practice.

Quantifying Intrahepatic Viral Reservoirs

The researchers evaluated liver tissue samples from 56 treatment-naive participants enrolled in the North American Hepatitis B Research Network, comprising 24 individuals who were hepatitis B e antigen (HBeAg) positive and 32 who were HBeAg negative. To distinguish between the two primary sources of viral protein, the study employed rigorous molecular techniques to isolate covalently closed circular DNA (cccDNA, the stable viral mini-chromosome that persists in the nucleus and drives active replication). For this analysis, extracted DNA was heat-denatured and digested by a specialized enzyme to remove other DNA forms before quantification via real-time polymerase chain reaction. To identify integrated hepatitis B virus DNA (iDNA, viral genetic material permanently inserted into the host genome), the researchers used a hybridization-targeted next-generation sequencing assay. This technique pinpointed the exact junction sequences where viral DNA merged with human chromosomes. The analysis demonstrated that intrahepatic cccDNA, serum HBV DNA, HBV RNA, hepatitis B core-related antigen, and quantitative hepatitis B surface antigen (HBsAg) were all higher in HBeAg-positive chronic hepatitis B compared to HBeAg-negative cases. For practicing physicians, these findings reinforce that the e-antigen positive phase is characterized by high levels of active viral replication and protein expression from the episomal reservoir, whereas the landscape of viral persistence shifts dramatically as the disease progresses.

The Shift from Replication to Integration

Histological analysis of liver tissue revealed a stark divergence in viral protein expression as patients transitioned from the e-antigen positive to the e-antigen negative phase. Intrahepatic hepatitis B core antigen staining, a marker of active viral replication, was present in 87% of HBeAg-positive samples but dropped to only 13% in HBeAg-negative samples (p < 0.0001). Despite this significant reduction in core protein production, the presence of the surface antigen remained nearly universal across both cohorts. Specifically, HBsAg staining was frequent in over 85% of samples in both the HBeAg-positive and HBeAg-negative groups. This clinical observation highlights a common frustration in practice: the mechanisms sustaining surface antigen production are distinct from those driving active viral replication, explaining why nucleos(t)ide analogues effectively suppress viral load but rarely achieve HBsAg clearance. The researchers identified the genomic source of this persistent surface antigen by quantifying the proportion of iDNA. In the HBeAg-positive cohort, the vast majority of viral DNA remained in a non-integrated state; 23 (95.8%) HBeAg-positive participants had 50% or less iDNA of the total hepatitis B virus DNA in their livers. Conversely, the genomic landscape shifted significantly in the later stage of the disease. Among the HBeAg-negative cohort, 25 (78.1%) participants had more than 50% iDNA of the total hepatitis B virus DNA in their livers. These findings indicate that while the cccDNA reservoir drives early infection, integrated sequences become the primary template for surface antigen production in HBeAg-negative patients.

Clonal Expansion and Integration Patterns

The molecular architecture of viral integration undergoes a significant transformation as chronic hepatitis B progresses. In the early HBeAg-positive phase, the researchers found that the virus frequently utilizes microhomology-mediated end joining (an error-prone cellular DNA repair pathway that the virus exploits to insert its genetic material into the host genome). This mechanism resulted in a highly varied integration landscape. Specifically, in HBeAg-positive chronic hepatitis B, integrated DNA (iDNA) sites were largely random, with only 15.9% of integrations localized to the direct repeat 2 (DR2)-DR1 region, a specific viral sequence highly prone to breaking and integrating. As the disease transitions to the HBeAg-negative phase, the genomic profile of the virus shifts from random insertion to highly localized clustering. The study determined that 52.4% of the iDNA integrations in HBeAg-negative chronic hepatitis B were clustered at the DR2-DR1 region, a stark contrast to the early-stage randomness. This high frequency of DR2-DR1 distribution suggests a selection advantage and clonal expansion, a process where specific hepatocytes containing these particular viral integrants survive immune clearance and multiply. This clonal dominance explains how a specific viral sequence can become widespread throughout the liver tissue even as active viral replication diminishes. Ultimately, the researchers observed that HBeAg-negative chronic hepatitis B was associated with high HBsAg staining concentration despite low levels of cccDNA. Because HBsAg can be derived from both sources, the exhaustion of the cccDNA reservoir does not lead to surface antigen loss. Instead, the data indicate that iDNA serves as the primary source of HBsAg in HBeAg-negative chronic hepatitis B. For clinicians, this underscores that achieving a functional cure will likely require future therapies designed not just to halt viral replication, but to specifically target or silence these integrated viral sequences.

References

1. Mohareb AM, Liu AF, Kim AY, et al. Clearance of Hepatitis B e Antigen in Untreated Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-analysis.. The Journal of infectious diseases. 2022. doi:10.1093/infdis/jiac168

2. Sarin SK, Kumar M, Lau G, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatology International. 2015. doi:10.1007/s12072-015-9675-4

3. Terrault NA, Lok AS, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018. doi:10.1002/hep.29800

4. Kennedy P, Lee HC, Jeyalingam L, et al. NICE Guidelines and a Treatment Algorithm for the Management of Chronic Hepatitis B: A Review of 12 Years Experience in West London. Antiviral Therapy. 2008. doi:10.1177/135965350801300807

5. Kim V, Abreu RM, Nakagawa DM, Baldassare RM, Carrilho FJ, Ono SK. Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis.. Journal of viral hepatitis. 2016. doi:10.1111/jvh.12418